Cargando…

Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience

PURPOSE: This series reports long-term clinical outcomes of patients with salivary duct carcinoma (SDC), which is associated with a poor prognosis. METHODS AND MATERIALS: Eighty-nine patients with SDC were treated with curative intent from February 5, 1971, through September 15, 2018. Kaplan-Meier a...

Descripción completa

Detalles Bibliográficos
Autores principales: Laughlin, Brady S., Ebrahimi, Sasha, Voss, Molly M., Patel, Samir H., Foote, Robert L., McGee, Lisa A., Garcia, Joaquin, Ma, Daniel J., Garces, Yolanda I., Wittich, Michelle A. Neben, Price, Katharine A., Schmitt, Alessandra, Zhai, Qihui, May, Byron C., Nagel, Thomas H., Hinni, Michael L., Chintakuntlawar, Ashish V., DeWees, Todd A., Rwigema, Jean-Claude M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157113/
https://www.ncbi.nlm.nih.gov/pubmed/37152485
http://dx.doi.org/10.1016/j.adro.2023.101204
_version_ 1785036678501498880
author Laughlin, Brady S.
Ebrahimi, Sasha
Voss, Molly M.
Patel, Samir H.
Foote, Robert L.
McGee, Lisa A.
Garcia, Joaquin
Ma, Daniel J.
Garces, Yolanda I.
Wittich, Michelle A. Neben
Price, Katharine A.
Schmitt, Alessandra
Zhai, Qihui
May, Byron C.
Nagel, Thomas H.
Hinni, Michael L.
Chintakuntlawar, Ashish V.
DeWees, Todd A.
Rwigema, Jean-Claude M.
author_facet Laughlin, Brady S.
Ebrahimi, Sasha
Voss, Molly M.
Patel, Samir H.
Foote, Robert L.
McGee, Lisa A.
Garcia, Joaquin
Ma, Daniel J.
Garces, Yolanda I.
Wittich, Michelle A. Neben
Price, Katharine A.
Schmitt, Alessandra
Zhai, Qihui
May, Byron C.
Nagel, Thomas H.
Hinni, Michael L.
Chintakuntlawar, Ashish V.
DeWees, Todd A.
Rwigema, Jean-Claude M.
author_sort Laughlin, Brady S.
collection PubMed
description PURPOSE: This series reports long-term clinical outcomes of patients with salivary duct carcinoma (SDC), which is associated with a poor prognosis. METHODS AND MATERIALS: Eighty-nine patients with SDC were treated with curative intent from February 5, 1971, through September 15, 2018. Kaplan-Meier and competing risk analyses were used to estimate locoregional control, distant metastasis-free survival (DMFS), progression-free survival, and overall survival (OS). Cox regression analyses of disease and treatment characteristics were performed to discover predictors of locoregional control, DMFS, and OS. RESULTS: Median follow-up was 44.1 months (range, 0.23-356.67). The median age at diagnosis was 66 years (interquartile range, 57-75). Curative surgery followed by adjuvant radiation therapy was performed in 73 patients (82%). Chemotherapy was delivered in 26 patients (29.2%). The 5-year local recurrence and distant metastasis rates were 27% and 44%, respectively, with death as a competing risk. Distant metastasis was associated with lymph node–positive disease (hazard ratio [HR], 3.16; 95% confidence interval [CI], 1.38-7.23; P = .006), stage IV disease (HR, 4.78; 95% CI, 1.14-20.11; P = .033), perineural invasion (HR, 4.56; 95% CI, 1.74-11.97; P = .002), and positive margins (HR, 9.06; 95% CI, 3.88-21.14; P < .001). Median OS was 4.84 years (95% CI, 3.54-7.02). The 5-year OS was 42%. Reduced OS was associated with lymphovascular space invasion (HR, 3.49; 95% CI, 1.2-10.1; P = .022), perineural invasion (HR, 2.05; 95% CI, 1.06-3.97; P = .033), positive margins (HR, 2.7; 95% CI, 1.3-5.6; P = .011), N2 disease (HR, 1.88; 95% CI, 1.03-3.43; P = .04), and N3 disease (HR, 11.76; 95% CI, 3.19-43.3; P < .001). CONCLUSIONS: In this single-institution, multicenter retrospective study, the 5-year survival was 42% in patients with SDC. Lymphovascular space invasion, lymph node involvement, and higher staging at diagnosis were associated with lower DMFS and OS.
format Online
Article
Text
id pubmed-10157113
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101571132023-05-05 Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience Laughlin, Brady S. Ebrahimi, Sasha Voss, Molly M. Patel, Samir H. Foote, Robert L. McGee, Lisa A. Garcia, Joaquin Ma, Daniel J. Garces, Yolanda I. Wittich, Michelle A. Neben Price, Katharine A. Schmitt, Alessandra Zhai, Qihui May, Byron C. Nagel, Thomas H. Hinni, Michael L. Chintakuntlawar, Ashish V. DeWees, Todd A. Rwigema, Jean-Claude M. Adv Radiat Oncol Scientific Article PURPOSE: This series reports long-term clinical outcomes of patients with salivary duct carcinoma (SDC), which is associated with a poor prognosis. METHODS AND MATERIALS: Eighty-nine patients with SDC were treated with curative intent from February 5, 1971, through September 15, 2018. Kaplan-Meier and competing risk analyses were used to estimate locoregional control, distant metastasis-free survival (DMFS), progression-free survival, and overall survival (OS). Cox regression analyses of disease and treatment characteristics were performed to discover predictors of locoregional control, DMFS, and OS. RESULTS: Median follow-up was 44.1 months (range, 0.23-356.67). The median age at diagnosis was 66 years (interquartile range, 57-75). Curative surgery followed by adjuvant radiation therapy was performed in 73 patients (82%). Chemotherapy was delivered in 26 patients (29.2%). The 5-year local recurrence and distant metastasis rates were 27% and 44%, respectively, with death as a competing risk. Distant metastasis was associated with lymph node–positive disease (hazard ratio [HR], 3.16; 95% confidence interval [CI], 1.38-7.23; P = .006), stage IV disease (HR, 4.78; 95% CI, 1.14-20.11; P = .033), perineural invasion (HR, 4.56; 95% CI, 1.74-11.97; P = .002), and positive margins (HR, 9.06; 95% CI, 3.88-21.14; P < .001). Median OS was 4.84 years (95% CI, 3.54-7.02). The 5-year OS was 42%. Reduced OS was associated with lymphovascular space invasion (HR, 3.49; 95% CI, 1.2-10.1; P = .022), perineural invasion (HR, 2.05; 95% CI, 1.06-3.97; P = .033), positive margins (HR, 2.7; 95% CI, 1.3-5.6; P = .011), N2 disease (HR, 1.88; 95% CI, 1.03-3.43; P = .04), and N3 disease (HR, 11.76; 95% CI, 3.19-43.3; P < .001). CONCLUSIONS: In this single-institution, multicenter retrospective study, the 5-year survival was 42% in patients with SDC. Lymphovascular space invasion, lymph node involvement, and higher staging at diagnosis were associated with lower DMFS and OS. Elsevier 2023-03-01 /pmc/articles/PMC10157113/ /pubmed/37152485 http://dx.doi.org/10.1016/j.adro.2023.101204 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Laughlin, Brady S.
Ebrahimi, Sasha
Voss, Molly M.
Patel, Samir H.
Foote, Robert L.
McGee, Lisa A.
Garcia, Joaquin
Ma, Daniel J.
Garces, Yolanda I.
Wittich, Michelle A. Neben
Price, Katharine A.
Schmitt, Alessandra
Zhai, Qihui
May, Byron C.
Nagel, Thomas H.
Hinni, Michael L.
Chintakuntlawar, Ashish V.
DeWees, Todd A.
Rwigema, Jean-Claude M.
Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
title Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
title_full Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
title_fullStr Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
title_full_unstemmed Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
title_short Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience
title_sort clinicopathologic factors and their association with outcomes of salivary duct carcinoma: a multicenter experience
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157113/
https://www.ncbi.nlm.nih.gov/pubmed/37152485
http://dx.doi.org/10.1016/j.adro.2023.101204
work_keys_str_mv AT laughlinbradys clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT ebrahimisasha clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT vossmollym clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT patelsamirh clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT footerobertl clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT mcgeelisaa clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT garciajoaquin clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT madanielj clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT garcesyolandai clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT wittichmichelleaneben clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT pricekatharinea clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT schmittalessandra clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT zhaiqihui clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT maybyronc clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT nagelthomash clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT hinnimichaell clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT chintakuntlawarashishv clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT deweestodda clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience
AT rwigemajeanclaudem clinicopathologicfactorsandtheirassociationwithoutcomesofsalivaryductcarcinomaamulticenterexperience